Panel Components:
CD5, CD10, CD19, CD20, CD34, CD38, CD45, kappa, lambda

Methodology: FLOW

Clinical Significance:
This panel is designed to detect residual B-ALL after therapy, and includes antibodies to CD45, kappa, lambda, CD5, CD34, CD20, CD10, CD19, and CD38.

Organ: Blood/Bone Marrow

Disease State: Precursor B-Lymphoblastic Lymphoma/Leukemia (B-ALL)

CPT Code(s): 88184 x 1, 88185 x 8, 88188 x 1 (reference only; CPTs may vary)

Turnaround Time: Physician will be contacted by 9:00 PM PST the day of receipt for acute/life threatening conditions; next business day for routine flow cases.

Schedule: Monday-Saturday

Specimen Requirements:
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR -
• Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR -
• Tissue: Finely minced tissue in RPMI transport media - OR -
• Body fluids: In RPMI transport media